title: Treatment of chronic hepatitis B in Asia-Pacific countries: is the Asia-Pacific consensus statement being followed?
abstract: BACKGROUND
  The Asia-Pacific consensus guidelines for the management of chronic hepatitis B state that the principal indicators for starting therapy are increased HBV DNA levels (> or =20,000 IU/ml for hepatitis B e antigen [HBeAg]-positive status and >2,000 IU/ml for HBeAg-negative status) and alanine aminotransferase (ALT) levels >2x the upper limit of normal. We aimed to determine whether clinicians in the Asia-Pacific region are treating patients with chronic hepatitis B according to the Asia-Pacific consensus statement on the management of chronic hepatitis B.
  
  
  METHODS
  An online survey of chronic hepatitis B treatment practices was prepared, consisting of 14 questions grouped into seven categories: patient statistics, treatment statistics, treatment decision, first-choice treatment, treatment duration, future directions and patient preference.
  
  
  RESULTS
  In total, 124 respondents from 12 countries completed the survey. Most respondents indicated that detectable HBV DNA was either the first or second most important factor when deciding whether to initiate therapy. Many physicians were unsure about initiation of treatment in patients >40 years of age when ALT levels were within the normal range. Oral antiviral drugs were the most frequently used medication because of their effectiveness, safety and ability to provide sustained viral suppression. Conversely, the most important reasons for selecting interferon therapy were effectiveness, fixed duration of treatment and lack of drug resistance. Criteria for stopping treatment generally followed the recommendations included in the guidelines.
  
  
  CONCLUSIONS
  These data suggest that clinicians from the Asia-Pacific region use criteria beyond those advocated in treatment guidelines when deciding whether to initiate treatment in HBV-infected patients.
authors.affiliation: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong. joesung@cuhk.edu.hk
authors.forename: Joseph J Y
authors.initials: JJ
authors.lastname: Sung
authors.forename: Deepak
authors.initials: D
authors.lastname: Amarapurkar
authors.forename: Henry L Y
authors.initials: HL
authors.lastname: Chan
authors.forename: Jun
authors.initials: J
authors.lastname: Cheng
authors.forename: Jia-Horng
authors.initials: JH
authors.lastname: Kao
authors.forename: Kwang-Hyub
authors.initials: KH
authors.lastname: Han
authors.forename: Teerha
authors.initials: T
authors.lastname: Piratvisuth
mesh_terms: D006801:Humans; D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001208:Asia; D001315:Australia; D004279:DNA, Viral / Q000097:blood; D004334:Drug Administration Schedule; D005762:Gastroenterology / Q000592:standards; D019983:Guideline Adherence; D017408:Guidelines as Topic / Q000592:standards; D006513:Hepatitis B e Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000187:drug effects / Q000235:genetics / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000188:drug therapy / Q000821:virology; D020407:Internet; D010818:Practice Patterns, Physicians'; D011795:Surveys and Questionnaires; D003245:Consensus Statements as Topic
chemical_list: D000410:Alanine Transaminase; D000998:Antiviral Agents; D004279:DNA, Viral; D006513:Hepatitis B e Antigens